Cold Sintering Process for Fabrication of Biodegradable Drug-Eluting Ceramics

Informations projet

DrugCer

N° de convention de subvention: 101063841

DOI

10.3030/101063841

Projet clôturé

Date de signature de la CE 9 Août 2022

Date de début 1 Août 2023

Date de fin 31 Juillet 2025

Financé au titre de

• Marie Skłodowska-Curie Actions (MSCA)

Coût total

Aucune donnée

Contribution de l’UE

€ 189 687,36

Coordonné par

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany

Periodic Reporting for period 1 - DrugCer (Cold Sintering Process for Fabrication of Biodegradable Drug-Eluting Ceramics)

Période du rapport: 2023-08-01 au 2025-07-31

Résumé du contexte et des objectifs généraux du projet

The project DrugCer – Cold Sintering Process for the Fabrication of Biodegradable Drug-Eluting Ceramics aimed to develop a sustainable manufacturing route for bioceramics with controlled drug release and bone-like mechanical performance. Conventional sintering requires temperatures above 1000 °C, which limits the integration of drugs, polymers, and metals. The Cold Sintering Process (CSP) overcomes this barrier by enabling densification of materials at near-room temperatures under high pressure. This approach reduces energy use and CO2 emissions while opening new opportunities for multifunctional biomedical materials.
The project focused on creating biodegradable ceramic–polymer composites that can release therapeutic agents and provide strength comparable to that of compact bone. Beyond developing drug-eluting bioceramics, a new concept for bioceramics with embedded metallic lines was proposed. Such functional bioceramics hold potential for bone-integrated sensors and neural interfaces. These materials could bridge the gap between hard implants and flexible electronics, contributing to future human–machine interfaces.
The project addressed EU strategic priorities by reducing the environmental footprint of ceramic manufacturing (European Green Deal), promoting technological innovation in the health and materials sectors (An Economy that Works for People), and supporting medical technologies that improve the quality of life (European Way of Life).

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The project developed and optimized Cold Sintering Process (CSP) routes for hydroxyapatite–gelatin (HAp–gelatin) composites. The process preserved the flake-like nanostructure of hydroxyapatite and yielded materials with strength and ductility similar to those of bone. Bioceramic–polymer composites loaded with 1 wt% of the antibiotic vancomycin showed a compressive strength of approximately 186 MPa, comparable to the 200 MPa strength of natural bone, and a ductile fracture behavior.
The mechanisms of densification and drug release were studied through a short research stay at the G.E.R.N. Center for Tissue Replacement, Regeneration, and Neogenesis at the University of Freiburg. Drug-release kinetics were quantified using high-performance liquid chromatography (HPLC), revealing a Case II transport mechanism consistent with controlled diffusion. These results represent the first demonstration of drug-release modeling for cold-sintered ceramic–polymer composites.
In parallel, new work packages were implemented to explore bioceramic–metal co-sintering. Metallic lines were inkjet-printed and successfully embedded into ceramic matrices using cold sintering, establishing a stable metal–ceramic interface formed at room temperature. This technology allows the fabrication of functional bioceramics capable of electrical transmission and stimulation, expanding the scope of CSP toward active biomedical implants.
Scientific results from the project were published (Open Ceramics, Journal of the European Ceramic Society, Fraunhofer Annual Report 2024/25) and presented at international conferences (World Biomaterials Congress 2024, Israel Materials Engineering Conference 2025, Conference of European Ceramics Society 2025).

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The project demonstrated that cold sintering enables the co-processing of ceramics, polymers, and metals in a single step, unachievable by conventional high-temperature sintering. These possibilities open new pathways for biohybrid materials that combine mechanical strength, drug release, biodegradability, and electrical functionality.
Key results of the project include:
• Dense, bone-like hydroxyapatite–gelatin composites that mimic bone in composition and microstructure;
• Dense, drug-eluting bioceramics and an identified model for drug-release kinetics from the developed materials;
• A concept for bioceramics with embedded metallization with potential for bone-integrated electrodes and sensors.
The results provide a foundation for further development of cold-sintered hybrid implants, conductive bone implants, and drug-delivery devices. The technology is currently at TRL 2–4 (proof of concept to early validation). Engagement with medical and industrial partners during project implementation led to follow-up grant applications (M-ERA.Net 2024, BMBF MaterialVital 2025) and ongoing collaborations with universities and startups in Germany, Denmark, Israel, and the Netherlands. Continued research and cooperation with industrial and medical partners are necessary for advancing the technology toward higher TRLs.